KalVista Pharmaceuticals
Market Cap
US$120.5m
Last Updated
2020/04/02 08:58 UTC
Data Sources
Company Financials +
Executive Summary
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Share Price & News
How has KalVista Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: KALV's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-12.2%
KALV
2.0%
US Biotechs
-1.1%
US Market
1 Year Return
-77.4%
KALV
-1.1%
US Biotechs
-13.6%
US Market
Return vs Industry: KALV underperformed the US Biotechs industry which returned 1.6% over the past year.
Return vs Market: KALV underperformed the US Market which returned -10.7% over the past year.
Shareholder returns
| KALV | Industry | Market | |
|---|---|---|---|
| 7 Day | -12.2% | 2.0% | -1.1% |
| 30 Day | -52.7% | -7.8% | -17.8% |
| 90 Day | -60.8% | -6.0% | -22.5% |
| 1 Year | -77.4%-77.4% | -0.3%-1.1% | -11.9%-13.6% |
| 3 Year | -11.4%-11.4% | 13.0%10.2% | 12.1%4.9% |
| 5 Year | n/a | -7.6%-11.8% | 30.5%16.3% |
Price Volatility Vs. Market
How volatile is KalVista Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
KalVista Pharmaceuticals, Inc. Analysts Are Cutting Their Estimates: Here's What You Need To Know1 month ago | Simply Wall St
Does KalVista Pharmaceuticals, Inc.'s (NASDAQ:KALV) CEO Pay Matter?2 months ago | Simply Wall St
Here's Why We're Not Too Worried About KalVista Pharmaceuticals's (NASDAQ:KALV) Cash Burn SituationValuation
Is KalVista Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
1.34x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate KALV's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate KALV's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: KALV is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: KALV is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KALV's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KALV is good value based on its PB Ratio (1.5x) compared to the US Biotechs industry average (2.6x).
Next Steps
Future Growth
How is KalVista Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
39.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: KALV is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: KALV is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: KALV is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: KALV's revenue (65.6% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: KALV's revenue (65.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if KALV's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has KalVista Pharmaceuticals performed over the past 5 years?
-11.2%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KALV is currently unprofitable.
Growing Profit Margin: KALV is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: KALV is unprofitable, and losses have increased over the past 5 years at a rate of -11.2% per year.
Accelerating Growth: Unable to compare KALV's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KALV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: KALV has a negative Return on Equity (-34.61%), as it is currently unprofitable.
Next Steps
Financial Health
How is KalVista Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: KALV's short term assets ($99.0M) exceed its short term liabilities ($9.8M).
Long Term Liabilities: KALV's short term assets ($99.0M) exceed its long term liabilities ($3.4M).
Debt to Equity History and Analysis
Debt Level: KALV is debt free.
Reducing Debt: KALV has not had any debt for past 5 years.
Balance Sheet
Inventory Level: KALV has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if KALV's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KALV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KALV has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -25.2% each year.
Next Steps
Dividend
What is KalVista Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate KALV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate KALV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if KALV's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if KALV's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of KALV's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.4yrs
Average management tenure
CEO
Andy Crockett (44yo)
3.42s
Tenure
US$3,287,944
Compensation
Mr. Thomas Andrew Crockett, also known as Andy, M.B.A., has been Chief Executive Officer and Director of KalVista Pharmaceuticals, Inc. since November 21, 2016. Mr. Crockett is the Founder of KalVista Pha ...
CEO Compensation Analysis
Compensation vs Market: Andy's total compensation ($USD3.29M) is above average for companies of similar size in the US market ($USD605.16K).
Compensation vs Earnings: Andy's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.42yrs | US$3.29m | 1.33% $1.6m | |
| Chief Business Officer & CFO | 3.67yrs | US$2.09m | 0.18% $219.4k | |
| Chief Scientific Officer | 3.42yrs | US$1.59m | 0.54% $652.3k | |
| Director of Corporate Communications & Investor Relations | no data | no data | no data | |
| Head of Regulatory Affairs and QA | no data | no data | no data | |
| Chief Development Officer | 3.42yrs | no data | 0.46% $559.4k | |
| Senior Vice President of Medical | 3.08yrs | US$416.74k | no data | |
| Senior Vice President of Development | 0.33yr | no data | no data | |
| Director of Finance and Company Secretary | no data | no data | no data | |
| Vice President of Finance | no data | US$516.08k | no data |
3.4yrs
Average Tenure
54yo
Average Age
Experienced Management: KALV's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.42yrs | US$3.29m | 1.33% $1.6m | |
| Director | 3.42yrs | US$165.34k | no data | |
| Chairman | 0.83yr | no data | no data | |
| Director | 3.42yrs | US$165.34k | no data | |
| Director | 3.42yrs | US$165.97k | no data | |
| Director | 1yr | US$264.78k | 0.056% $67.5k | |
| Director | 1.17yrs | US$191.48k | no data | |
| Board Observer | 4.75yrs | no data | no data | |
| Board Observer | 4.75yrs | no data | no data |
3.4yrs
Average Tenure
61.5yo
Average Age
Experienced Board: KALV's board of directors are considered experienced (3.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.4%.
Top Shareholders
Company Information
KalVista Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: KalVista Pharmaceuticals, Inc.
- Ticker: KALV
- Exchange: NasdaqGM
- Founded:
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$120.458m
- Shares outstanding: 17.85m
- Website: https://www.kalvista.com
Number of Employees
Location
- KalVista Pharmaceuticals, Inc.
- 55 Cambridge Parkway
- Suite 901 East
- Cambridge
- Massachusetts
- 2142
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| KALV | NasdaqGM (Nasdaq Global Market) | Yes | New Ordinary Shares | US | USD | Nov 2016 |
| 4XC1 | DB (Deutsche Boerse AG) | Yes | New Ordinary Shares | DE | EUR | Nov 2016 |
Biography
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; KVD900, which is in Phase II clinical trial for treating HAE; and KVD824, an oral plasma kallikrein inhibitor that is in Phase I clinical trial for treating DME or HAE. The company is headquartered in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/02 08:58 |
| End of Day Share Price | 2020/04/01 00:00 |
| Earnings | 2020/01/31 |
| Annual Earnings | 2019/04/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.